JP2013504603A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013504603A5 JP2013504603A5 JP2012529062A JP2012529062A JP2013504603A5 JP 2013504603 A5 JP2013504603 A5 JP 2013504603A5 JP 2012529062 A JP2012529062 A JP 2012529062A JP 2012529062 A JP2012529062 A JP 2012529062A JP 2013504603 A5 JP2013504603 A5 JP 2013504603A5
- Authority
- JP
- Japan
- Prior art keywords
- csf
- antibody
- cns
- use according
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 38
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 38
- 210000003169 central nervous system Anatomy 0.000 claims description 17
- 230000002757 inflammatory effect Effects 0.000 claims description 12
- 230000000626 neurodegenerative effect Effects 0.000 claims description 12
- 230000000692 anti-sense effect Effects 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 230000008685 targeting Effects 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 239000003018 immunosuppressive agent Substances 0.000 claims description 4
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000008595 infiltration Effects 0.000 claims description 3
- 238000001764 infiltration Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 210000000440 neutrophil Anatomy 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24250309P | 2009-09-15 | 2009-09-15 | |
| US61/242,503 | 2009-09-15 | ||
| PCT/AU2010/001191 WO2011032204A1 (en) | 2009-09-15 | 2010-09-14 | Treatment of neurological conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015109380A Division JP2015187135A (ja) | 2009-09-15 | 2015-05-29 | 神経疾患の処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013504603A JP2013504603A (ja) | 2013-02-07 |
| JP2013504603A5 true JP2013504603A5 (enExample) | 2013-10-10 |
| JP5785550B2 JP5785550B2 (ja) | 2015-09-30 |
Family
ID=43757935
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012529062A Expired - Fee Related JP5785550B2 (ja) | 2009-09-15 | 2010-09-14 | 神経疾患の処置方法 |
| JP2015109380A Pending JP2015187135A (ja) | 2009-09-15 | 2015-05-29 | 神経疾患の処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015109380A Pending JP2015187135A (ja) | 2009-09-15 | 2015-05-29 | 神経疾患の処置方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9364534B2 (enExample) |
| EP (1) | EP2477656B1 (enExample) |
| JP (2) | JP5785550B2 (enExample) |
| KR (1) | KR101750426B1 (enExample) |
| CN (1) | CN102630167B (enExample) |
| AU (1) | AU2010295223B2 (enExample) |
| CA (1) | CA2773552C (enExample) |
| DK (1) | DK2477656T3 (enExample) |
| ES (1) | ES2623802T3 (enExample) |
| PL (1) | PL2477656T3 (enExample) |
| WO (1) | WO2011032204A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110117092A1 (en) * | 2009-10-20 | 2011-05-19 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting g-csfr |
| CA2838246C (en) * | 2011-06-13 | 2018-07-10 | Csl Limited | Antibodies against g-csfr and uses thereof |
| GB201401465D0 (en) * | 2014-01-29 | 2014-03-12 | Roach Arthur H | Use of cladribine for treating autoimmune inflammatory disease |
| PL3717011T3 (pl) | 2017-11-29 | 2023-03-27 | Csl Limited | Sposób leczenia lub zapobiegania uszkodzeniu niedokrwienno- reperfuzyjnemu |
| WO2019178645A1 (en) | 2018-03-23 | 2019-09-26 | Csl Limited | Method of treating asthma |
| WO2019226550A1 (en) * | 2018-05-21 | 2019-11-28 | CHS Pharma Inc. | Granulocyte colony-stimulating factor (gcsf) gene therapy for treating neurological diseases |
| KR102887037B1 (ko) * | 2018-12-04 | 2025-11-18 | 씨에스엘 이노베이션 피티와이 엘티디 | 호중구 질환을 치료하는 방법 |
| WO2025007195A1 (en) | 2023-07-05 | 2025-01-09 | CSL Innovation Pty Ltd | Methods of treating or preventing a complication of sickle cell disease |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IE66494B1 (en) | 1989-09-26 | 1996-01-10 | Immunex Corp | Granulocyte-colony stimulating factor receptors |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| WO1997042224A1 (en) * | 1996-05-07 | 1997-11-13 | Millennium Biotherapeutics, Inc. | Neurotactin and uses therefor |
| US8883856B2 (en) * | 2000-02-28 | 2014-11-11 | John Jackson | Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors |
| US7108852B2 (en) * | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
| CA2443050A1 (en) * | 2001-03-30 | 2002-10-10 | Philadelphia Health And Education Corporation | Immunomodulation and effect on cell processes relating to serotonin family receptors |
| DK1542528T3 (da) * | 2002-08-23 | 2010-02-01 | Inst Medical W & E Hall | Fremgangsmåde til behandling og profylakse |
| NZ543654A (en) * | 2003-05-23 | 2009-05-31 | Wyeth Corp | GITR ligand and GITR ligand-related molecules and antibodies and uses thereof |
| WO2005121174A2 (en) | 2004-06-04 | 2005-12-22 | Five Prime Therapeutics, Inc. | Novel g-csf polypeptides, polynucleotides, modulators thereof, and methods of use |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US7871979B2 (en) * | 2006-07-06 | 2011-01-18 | Merck Serono Sa | CSF3R polypeptides and uses thereof |
| EP2526959B1 (en) * | 2006-08-11 | 2017-08-02 | CSL Limited | Treatment of pulmonary disease conditions |
| WO2008125903A2 (en) | 2006-12-12 | 2008-10-23 | Chaim Sheba Medical Center | Method of inhibiting an undesired immune response |
-
2010
- 2010-09-14 DK DK10816462.5T patent/DK2477656T3/en active
- 2010-09-14 KR KR1020127008842A patent/KR101750426B1/ko active Active
- 2010-09-14 CA CA2773552A patent/CA2773552C/en active Active
- 2010-09-14 AU AU2010295223A patent/AU2010295223B2/en not_active Ceased
- 2010-09-14 JP JP2012529062A patent/JP5785550B2/ja not_active Expired - Fee Related
- 2010-09-14 CN CN201080048357.7A patent/CN102630167B/zh not_active Expired - Fee Related
- 2010-09-14 EP EP10816462.5A patent/EP2477656B1/en active Active
- 2010-09-14 WO PCT/AU2010/001191 patent/WO2011032204A1/en not_active Ceased
- 2010-09-14 ES ES10816462.5T patent/ES2623802T3/es active Active
- 2010-09-14 US US12/881,293 patent/US9364534B2/en active Active
- 2010-09-14 PL PL10816462T patent/PL2477656T3/pl unknown
-
2014
- 2014-03-24 US US14/223,315 patent/US9352038B2/en active Active
-
2015
- 2015-05-29 JP JP2015109380A patent/JP2015187135A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013504603A5 (enExample) | ||
| Yang et al. | CXCL12-CXCR4/CXCR7 axis in cancer: from mechanisms to clinical applications | |
| Matera et al. | TSLP inhibitors for asthma: current status and future prospects | |
| JP7395483B2 (ja) | ｍＲＮＡの細胞内送達のためのペプチドおよびナノ粒子 | |
| US10479997B2 (en) | Compositions and methods for diagnosis and treatment of prostate cancer | |
| US9150647B2 (en) | Biological inhibitors of ROR1 capable of inducing cell death | |
| US20180010132A1 (en) | Inhibition of prmt5 to treat mtap-deficiency-related diseases | |
| JP2021529780A (ja) | Ｎｌｒｐ３アンタゴニストを使用するｔｎｆ阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法 | |
| JP2013537418A5 (enExample) | ||
| JP2014076062A5 (enExample) | ||
| JP2017113019A5 (enExample) | ||
| JP2012067116A5 (enExample) | ||
| JP2006525796A5 (enExample) | ||
| JP2012521217A5 (enExample) | ||
| TWI500629B (zh) | 介白素－６抗體及其用途 | |
| JP2010500291A5 (enExample) | ||
| JP2010526153A5 (enExample) | ||
| AU2014268316B2 (en) | Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma | |
| JP2015522264A5 (enExample) | ||
| JP2019506862A5 (enExample) | ||
| JP2020511493A (ja) | セマフォリン−４ｄ抗体とエピジェネティック調節剤の組み合わせを用いたがんの処置方法 | |
| JP2024133495A (ja) | 組み合わせでのＷｎｔ阻害剤および抗ＰＤ－１抗体分子の投与スケジュール | |
| Dong et al. | Inhalable siRNA targeting IL-11 nanoparticles significantly inhibit bleomycin-induced pulmonary fibrosis | |
| BR112021014105A2 (pt) | Agente capaz de inibir a sinalização mediada por interleucina 11, uso do mesmo e método para tratamento ou prevenção da hepatotoxicidade e/ou um distúrbio, doença ou condição associada à hepatotoxicidade | |
| JP2018529661A5 (enExample) |